IGF2R and neoplasm: The radioimmunotherapy (RIT) of OS tumors with IGF2R-specific mAbs MEM-238 and 2G11, which are 188Rhenium-labeled (188Re-labeled) and 177Lutetium-labeled (177Lu-labeled), respectively, resulted in tumor growth inhibition and even regression in some mice, with acceptable safety.